Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma, Cutaneous Malignant × dabrafenib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Dermatologic 1

Conditions

Melanoma 9 Neoplasm Metastasis 3 Glioma 2 Skin Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Melanoma, Cutaneous Malignant 1 Hematologic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Adenocarcinoma 1

Interventions

pembrolizumab 1 nintedanib 1 dabrafenib 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Immuneering Corporation

Phase 1/2 Active not recruiting

DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡